Anxiety and Depression Are More Prevalent in Patients with Graves' Disease Than in Patients with Nodular Goitre
Overview
Oncology
Authors
Affiliations
Background And Objective: Graves' disease has been associated with an increased psychiatric morbidity. It is unclarified whether this relates to Graves' disease or chronic disease per se. The aim of our study was to estimate the prevalence of anxiety and depression symptoms in patients with Graves' disease compared to patients with another chronic thyroid disease, nodular goitre, and to investigate determinants of anxiety and depression in Graves' disease.
Methods: 157 cross-sectionally sampled patients with Graves' disease, 17 newly diagnosed, 140 treated, and 251 controls with nodular goitre completed the Hospital Anxiety and Depression Scale (HADS). The differences in the mean HADS scores between the groups were analysed using multiple linear regression, controlling for socio-demographic variables. HADS scores were also analysed dichotomized: a score >10 indicating probable 'anxiety'/probable 'depression'. Determinants of anxiety and depression symptoms in Graves' disease were examined using multiple linear regression.
Results: In Graves' disease levels of anxiety (p = 0.008) and depression (p = 0.014) were significantly higher than in controls. The prevalence of depression was 10% in Graves' disease versus 4% in nodular goitre (p = 0.038), anxiety was 18 versus 13% (p = 0.131). Symptoms of anxiety (p = 0.04) and depression (p = 0.01) increased with comorbidity. Anxiety symptoms increased with duration of Graves' disease (p = 0.04). Neither thyroid function nor autoantibody levels were associated with anxiety and depression symptoms.
Conclusions: Anxiety and depression symptoms were more severe in Graves' disease than in nodular goitre. Symptoms were positively correlated to comorbidity and duration of Graves' disease but neither to thyroid function nor thyroid autoimmunity.
Hallab A Sci Rep. 2025; 15(1):2526.
PMID: 39833340 PMC: 11747398. DOI: 10.1038/s41598-025-86703-7.
Evaluation of thyroid function tests among children with neurological disorders.
Meng H, Bigambo F, Gu W, Wang X, Li Y Front Endocrinol (Lausanne). 2024; 15:1498788.
PMID: 39717108 PMC: 11663650. DOI: 10.3389/fendo.2024.1498788.
Psychological aspects of Graves' ophthalmopathy.
Al-Badri W, Jellema H, Potvin A, van Nispen R, Bisschop P, Saeed P Endocr Connect. 2024; 13(9).
PMID: 39032509 PMC: 11378138. DOI: 10.1530/EC-24-0259.
Psychiatric complications in Graves' disease.
Holmberg M, Malmgren H, Berglund P, Johansson B, Filipsson Nystrom H Eur Thyroid J. 2024; 13(1).
PMID: 38215285 PMC: 10895301. DOI: 10.1530/ETJ-23-0247.
Quality of life, social support, and adherence in female patients with thyroid disorders.
Kollerits E, Zsila A, Matuszka B BMC Womens Health. 2023; 23(1):567.
PMID: 37919706 PMC: 10623692. DOI: 10.1186/s12905-023-02718-0.